You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Dow
AstraZeneca
Medtronic
McKesson

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

LANTUS Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for LANTUS

Identify potential brand extensions & biosimilar entrants

SponsorPhase
The Cleveland ClinicPhase 4
University of WashingtonPhase 4
Novo Nordisk A/SPhase 1

See all LANTUS clinical trials

Recent Litigation for LANTUS

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08

See all LANTUS litigation

PTAB Litigation
PetitionerDate
Mylan Pharmaceuticals Inc.,2017-06-05

See all LANTUS litigation

Company Disclosures: US Patents for LANTUS

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Get Started for $10 Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Get Started for $10 Medimpex Ets (LI) 2013-04-23 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Get Started for $10 Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 RX company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Get Started for $10 Medimpex Ets. (Balzers, LI) 2012-02-21 company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Get Started for $10 Medimpex Ets (LI) 2013-04-23 company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Get Started for $10 Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 company
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Get Started for $10 Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for LANTUS

These patents were identified by searching patent claims

International Patents for LANTUS

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2007018943   Get Started for $10
United Kingdom 0309154   Get Started for $10
Singapore 173858   Get Started for $10
Japan 2004501897   Get Started for $10
Australia 780877   Get Started for $10
Eurasian Patent Organization 201591174   Get Started for $10
Poland 2906595   Get Started for $10
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for LANTUS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300019 Netherlands   Get Started for $10 PRODUCT NAME: INSULINE GLARGINE,DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH GESCHIKT ZOUT; REGISTRATION NO/DATE: EU/1/00/134/001 - 007 20000609
C20170015 00230 Estonia   Get Started for $10 PRODUCT NAME: GLARGIIN-INSULIIN/LIKSISENATIID;REG NO/DATE: EU/1/16/1157 13.01.2017
34/2000 Austria   Get Started for $10 PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 - EU/1/00/134/007 20000609
2017030 Norway   Get Started for $10 PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REG. NO/DATE: EU/1/16/1157 20170125
285 12-2017 Slovakia   Get Started for $10 PRODUCT NAME: INZULIN GLARGIN/LIXISENATID VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1157 20170113
00C0023 France   Get Started for $10 PRODUCT NAME: INSULIN GLARGINE; NAT. REGISTRATION NO/DATE: EU/0/00/134/001 20000609; FIRST REGISTRATION: EU/1/00/134/001 20000609
2017/022 Ireland   Get Started for $10 PRODUCT NAME: A COMPOSITION COMPRISING INSULIN GLARGINE, OR A PHARMACOLOGICALLY TOLERABLE SAFT THEREOF, AND LIXISENATIDE, OR A PHARMACOLOGICALLY TOLERABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/16/1157 20170111
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.